MX337778B - Anticuerpos contra il-22 humana y usos para los mismos. - Google Patents
Anticuerpos contra il-22 humana y usos para los mismos.Info
- Publication number
- MX337778B MX337778B MX2013009826A MX2013009826A MX337778B MX 337778 B MX337778 B MX 337778B MX 2013009826 A MX2013009826 A MX 2013009826A MX 2013009826 A MX2013009826 A MX 2013009826A MX 337778 B MX337778 B MX 337778B
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- antibodies against
- against human
- antibodies
- uses therefor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un anticuerpo o fragmento del mismo que une a antígeno, qua se une específicamente a IL-22, caracterizado porque comprende: (a) un dominio VH con SEQ ID NO: 134, SEQ ID NO: 135 y SEQ ID NO: 136 y un dominio VL con SEQ ID NO: 137, SEQ ID NO: 138 y SEQ ID NO: 139; (b) un dominio VH con SEQ ID NO: 152, SEQ ID NO: 153 y SEQ ID NO: 154 y un dominio VL con SEQ ID NO: 155, SEQ ID NO: 156 y SEQ ID NO: 157; (c) un dominio VH con SEQ ID NO: 170, SEQ ID NO: 171 y SEQ ID NO: 172 y un dominio VL con SEQ ID NO: 173, SEQ ID NO: 174 y SEQ ID NO: 175; (d) un dominio VH con SEQ ID NO; 188, SEQ ID NO: 189 y SEQ ID NO: 190 y un dominio VL con SEQ ID NO: 191, SEQ ID NO: 192 y SEQ ID NO: 193; (e) un dominio VH con SEQ ID NO: 206, SEQ ID NO: 207 y SEQ ID NO: 208 y un dominio VL con SEQ ID N0: 209, SEQ ID NO: 210 y SEQ ID NO: 211; (e) un dominio VH con SEQ ID NO: 224, SEQ ID NO: 225 y SEQ ID NO: 226 y un dominio VL con SEQ ID NO: 227, SEQ ID NO: 228 y SEQ ID NO: 229; (g) un dominio VH con SEQ ID NO: 242, SEQ ID NO: 243 y SEQ ID NO: 244 y un dominio VL con SEQ ID NO: 245, SEQ ID NO: 246 y SEQ ID NO: 247; (h) un dominio VH con SEQ ID NO: 260, SEQ ID NO: 261 y SEQ ID NO: 262 y un dominio VL con SEQ ID NO: 263, SEQ ID NO: 264 y SEQ ID NO: 265; (i) un dominio VH con SEQ ID NO: 278, SEQ ID NO: 279 y SEQ ID NO: 280 y un dominio VL con SEQ ID NO: 281, SEQ ID NO: 282 y SEQ ID NO: 283; (j) un dominio VH con SEQ ID NO: 494, SEQ ID NO: 495 y SEQ ID NO: 496 y un dominio VL con SEQ ID NO: 497, SEQ ID NO: 498 y SEQ ID NO: 499; (k) un dominio VH con SEQ ID NO: 530, SEQ ID NO: 531 y SEQ ID NO: 532 y un dominio VL con SEQ ID NO: 533, SEQ ID NO: 534 y SEQ ID NO: 535; (l) un dominio VH con SEQ ID NO: 548, SEQ ID NO: 549 y SEQ ID NO: 550 y un dominio VL con SEQ ID NO: 551, SEQ ID NO: 552 y SEQ ID NO: 553; (m) un dominio VH con SEQ ID NO: 566, SEQ ID NO: S67 y SEQ ID NO: 568 y un dominio VL con SEQ ID NO: 569, SEQ ID NO: 570 y SEQ ID NO: 571; (n) un dominio VH con SEQ ID NO: 584, SEQ ID N0: S85 y SEQ ID NO: 586 y un dominio VL con SEQ ID NO: 587, SEQ ID NO: 588 y SEQ ID NO: 589; (o) un dominio VH con SEQ ID NO: 602, SEQ ID NO: 603 y SEQ ID NO: 604 y un dominio VL con SEQ ID NO: 605, SEQ ID NO: 606 y SEQ ID NO: 607; o (p) un dominio VH con SEQ ID NO: 620, SEQ ID N0: 621 y SEQ ID NO: 622 y un dominio VL con SEQ ID NO: 623, SEQ ID NO: 624 y SEQ ID NO: 625; y en donde (i) la constante de asociación del anticuerpo para IL-22 humano es por lo menos 1010 M-1, (ii) el anticuerpo bloquea la proliferación mediada por IL-22 de células BaF3 con un CI50 de 150 pM o menor y en donde las células BaF3 comprenden un receptor IL-22 humano; o (iii) el anticuerpo bloquea la secreción de GROa mediada por IL-22 de células HT29 con un C150 de 150 pM o menor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77459606P | 2006-02-21 | 2006-02-21 | |
| PCT/US2007/004430 WO2007098170A1 (en) | 2006-02-21 | 2007-02-21 | Antibodies against human il-22 and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX337778B true MX337778B (es) | 2016-03-18 |
Family
ID=38236225
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008010708A MX2008010708A (es) | 2006-02-21 | 2007-02-21 | Anticuerpos contra il-22 humana y usos para los mismos. |
| MX2013009826A MX337778B (es) | 2006-02-21 | 2007-02-21 | Anticuerpos contra il-22 humana y usos para los mismos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008010708A MX2008010708A (es) | 2006-02-21 | 2007-02-21 | Anticuerpos contra il-22 humana y usos para los mismos. |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US7901684B2 (es) |
| EP (3) | EP1991584B1 (es) |
| JP (1) | JP5150516B2 (es) |
| KR (2) | KR20080113214A (es) |
| CN (1) | CN101426816B (es) |
| AR (1) | AR059604A1 (es) |
| AT (1) | ATE538137T1 (es) |
| AU (1) | AU2007217751B2 (es) |
| BR (1) | BRPI0708101B8 (es) |
| CA (1) | CA2643226C (es) |
| CR (1) | CR10237A (es) |
| DK (2) | DK3020729T3 (es) |
| EC (1) | ECSP088751A (es) |
| ES (2) | ES2377463T3 (es) |
| HK (1) | HK1120813A1 (es) |
| HN (1) | HN2008001292A (es) |
| HU (1) | HUE044595T2 (es) |
| IL (1) | IL193605A (es) |
| MX (2) | MX2008010708A (es) |
| MY (1) | MY146664A (es) |
| NO (1) | NO20083715L (es) |
| NZ (1) | NZ570878A (es) |
| PE (1) | PE20080111A1 (es) |
| PL (2) | PL1991584T3 (es) |
| PT (2) | PT1991584E (es) |
| RU (1) | RU2467016C2 (es) |
| SA (1) | SA07280062B1 (es) |
| SG (1) | SG172628A1 (es) |
| SI (2) | SI1991584T1 (es) |
| TW (1) | TWI417301B (es) |
| WO (1) | WO2007098170A1 (es) |
| ZA (1) | ZA200807278B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2295026T3 (es) * | 1999-04-28 | 2008-04-16 | Genetics Institute, Llc | Proteinas gil-19/ae289 humanas y polinucleotidos que codifican las mismas. |
| RU2426742C2 (ru) | 2005-12-02 | 2011-08-20 | Дженентек, Инк. | Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| EP2337799A2 (en) * | 2008-08-28 | 2011-06-29 | Wyeth LLC | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
| EP2419733A4 (en) | 2009-04-13 | 2013-12-25 | Univ Leland Stanford Junior | METHODS AND DEVICES FOR DETECTING THE PRESENCE OF AN ANALYTE IN A SAMPLE |
| CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
| CN102652259B (zh) * | 2010-03-12 | 2016-07-27 | 小利兰·斯坦福大学托管委员会 | 基于磁性传感器的定量结合动力学分析 |
| WO2011139974A2 (en) * | 2010-05-03 | 2011-11-10 | Abbott Laboratories | Anti-pai-1 antibodies and methods of use thereof |
| CN103382223B (zh) * | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
| WO2014015133A1 (en) * | 2012-07-19 | 2014-01-23 | National Cheng Kung University | Treatment of osteoarthritis using il-20 antagonists |
| CA2878712A1 (en) * | 2012-08-31 | 2014-03-06 | arGEN-X BV | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
| EP3385277A1 (en) | 2013-03-15 | 2018-10-10 | F. Hoffmann-La Roche AG | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| CN105139918B (zh) * | 2015-06-26 | 2017-04-12 | 哈尔滨工业大学 | 一种柔板印刷用低银高性能导电浆料及其制备方法 |
| CN105601739B (zh) * | 2016-02-22 | 2019-01-18 | 王晨辉 | 一种人源化抗白介素22基因工程抗体及其应用 |
| WO2018039107A1 (en) * | 2016-08-22 | 2018-03-01 | Medimmune, Llc | Binding molecules specific for notch4 and uses thereof |
| CN110402393A (zh) * | 2016-11-24 | 2019-11-01 | 休伯特保健公司 | 疾病诊断的组合物 |
| CN117630386A (zh) | 2016-11-28 | 2024-03-01 | 中外制药株式会社 | 包含抗原结合结构域和运送部分的多肽 |
| KR102536314B1 (ko) * | 2018-05-23 | 2023-05-25 | 주식회사 휴벳바이오 | 질환의 진단용 조성물 |
| CN112292396A (zh) | 2018-06-05 | 2021-01-29 | 生物蛋白有限公司 | 抗il-22抗体，抗体片段，其免疫结合物及其用途 |
| EP3863602A1 (en) | 2018-10-11 | 2021-08-18 | Alivio Therapeutics, Inc. | Non-injectable hydrogel formulations for smart release |
| KR102226826B1 (ko) * | 2020-08-06 | 2021-03-11 | 주식회사 휴벳바이오 | 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물 |
| KR20230117588A (ko) | 2020-12-07 | 2023-08-08 | 유씨비 바이오파마 에스알엘 | 다중특이적 항체 및 항체 조합 |
| EP4255925A1 (en) | 2020-12-07 | 2023-10-11 | UCB Biopharma SRL | Antibodies against interleukin-22 |
| MX2023010238A (es) | 2021-03-02 | 2023-12-05 | Dana Farber Cancer Inst Inc | Métodos para tratar trastornos de glóbulos rojos. |
| WO2023110942A1 (en) | 2021-12-14 | 2023-06-22 | Charité-Universitätsmedizin Berlin | Prevention of impaired fracture healing |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| IL91501A (en) | 1988-09-02 | 1998-03-10 | Dyax Corp | Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| ES2287206T3 (es) | 1991-03-01 | 2007-12-16 | Dyax Corporation | Proceso para el desarrollo de mini-proteinas de union. |
| AU662148B2 (en) | 1991-04-10 | 1995-08-24 | Scripps Research Institute, The | Heterodimeric receptor libraries using phagemids |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5833976A (en) * | 1991-08-06 | 1998-11-10 | Schering Corporation | Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| GB9214857D0 (en) | 1992-07-13 | 1992-08-26 | Medical Res Council | Human nucleic acid fragments and their use |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| US5789192A (en) | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
| US5536637A (en) * | 1993-04-07 | 1996-07-16 | Genetics Institute, Inc. | Method of screening for cDNA encoding novel secreted mammalian proteins in yeast |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5674487A (en) * | 1994-09-28 | 1997-10-07 | Univ Jefferson | Method for treating autoimmune diseases |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| DE122004000004I1 (de) | 1996-02-09 | 2004-08-12 | Abott Biotechnology Ltd | Humane Antikörper welche an Humanen TNFalpha binden. |
| US20010006637A1 (en) * | 1996-04-19 | 2001-07-05 | Tohru Akahoshi | Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient |
| AU740043B2 (en) | 1996-06-27 | 2001-10-25 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
| US6492507B1 (en) * | 1996-10-23 | 2002-12-10 | Incyte Genomics, Inc. | Polynucleotides encoding human eosinophil-derived basic protein |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| US6551799B2 (en) * | 1999-12-07 | 2003-04-22 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| US20030032057A1 (en) * | 1997-08-26 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2002016611A2 (en) | 2000-08-24 | 2002-02-28 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| US6350892B1 (en) | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
| EP1049717B1 (en) * | 1998-01-23 | 2007-03-21 | F. Hoffmann-La Roche Ag | Antibodies against human il-12 |
| US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| JP2002516103A (ja) | 1998-05-29 | 2002-06-04 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | インターロイキン２１およびインターロイキン２２ |
| AU760224B2 (en) * | 1998-10-26 | 2003-05-08 | Wyeth | Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof |
| US7081528B2 (en) * | 1998-10-26 | 2006-07-25 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding T cell derived inducible factors |
| US6274710B1 (en) * | 1998-10-26 | 2001-08-14 | Ludwig Institute For Cancer Research | Antibodies which specifically bind T Cell inducible factors (TIFs) |
| CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
| BR0009323A (pt) | 1999-03-25 | 2002-01-08 | Knoll Gmbh | Anticorpos humanos que ligam a il-12 humana e métodos para a produção |
| US7307161B1 (en) * | 1999-04-28 | 2007-12-11 | Genetics Institute, Llc | Human Gil-19/AE289 polynucleotides |
| US6939545B2 (en) * | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| CA2373231A1 (en) * | 1999-05-19 | 2000-11-23 | Incyte Genomics, Inc. | Extracellular signaling molecules |
| AU5047600A (en) | 1999-05-27 | 2000-12-18 | Schering Corporation | Mammalian interleukin-10 homologs: il-d110 and il-d210 |
| ATE448246T1 (de) | 1999-06-15 | 2009-11-15 | Genentech Inc | Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung |
| WO2001040467A1 (en) * | 1999-12-03 | 2001-06-07 | Zymogenetics, Inc. | Human cytokine receptor |
| US20030170823A1 (en) * | 1999-12-23 | 2003-09-11 | Presnell Scott R. | Novel cytokine ZCYTO18 |
| EP1242600B1 (en) | 1999-12-23 | 2010-03-03 | ZymoGenetics, Inc. | Cytokine zcyto18 |
| CN1400968A (zh) | 2000-01-27 | 2003-03-05 | 美国氰胺公司 | 制备α－磺酰基异羟肟酸衍生物的方法 |
| KR101111103B1 (ko) * | 2000-02-10 | 2012-02-13 | 아보트 러보러터리즈 | 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법 |
| AU7303301A (en) | 2000-07-27 | 2002-02-13 | Ludwig Inst Cancer Res | Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| US20030012788A1 (en) * | 2000-07-27 | 2003-01-16 | Jean-Christophe Renauld | Method for influencing kinase pathways with IL-22 |
| US7094570B2 (en) * | 2003-03-11 | 2006-08-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7638604B2 (en) * | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| NZ527396A (en) | 2001-02-23 | 2007-12-21 | Genetics Inst Llc | Antibodies and fragments thereof for the binding of IL-22 and use therefore for treating inflammatory disorders |
| US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| US20020187512A1 (en) | 2001-09-10 | 2002-12-12 | Nagem Ronaldo Alves Pinto | Crystal structure of human interleukin-22 |
| IL164181A0 (en) | 2002-03-22 | 2005-12-18 | Zymogenetics Inc | Anti-il-tif antibodies and methods of using in inflammation |
| US7375192B2 (en) * | 2002-05-01 | 2008-05-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine beta-4 |
| US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| CN1839157A (zh) * | 2003-06-23 | 2006-09-27 | 遗传研究所公司 | 抗白介素－22抗体及其应用 |
| WO2007004788A1 (en) | 2005-07-04 | 2007-01-11 | Samsung Electronics Co., Ltd. | Position measuring system and method using wireless broadband (wibro) signal |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
-
2007
- 2007-02-16 TW TW096106166A patent/TWI417301B/zh active
- 2007-02-20 US US11/708,061 patent/US7901684B2/en active Active
- 2007-02-21 JP JP2008556389A patent/JP5150516B2/ja active Active
- 2007-02-21 SI SI200730795T patent/SI1991584T1/sl unknown
- 2007-02-21 CA CA2643226A patent/CA2643226C/en active Active
- 2007-02-21 KR KR1020087023020A patent/KR20080113214A/ko active Search and Examination
- 2007-02-21 AT AT07751204T patent/ATE538137T1/de active
- 2007-02-21 CN CN2007800140240A patent/CN101426816B/zh active Active
- 2007-02-21 PT PT07751204T patent/PT1991584E/pt unknown
- 2007-02-21 DK DK15184078.2T patent/DK3020729T3/da active
- 2007-02-21 SA SA07280062A patent/SA07280062B1/ar unknown
- 2007-02-21 BR BRPI0708101A patent/BRPI0708101B8/pt active IP Right Grant
- 2007-02-21 ES ES07751204T patent/ES2377463T3/es active Active
- 2007-02-21 SI SI200732116T patent/SI3020729T1/sl unknown
- 2007-02-21 MX MX2008010708A patent/MX2008010708A/es active IP Right Grant
- 2007-02-21 PL PL07751204T patent/PL1991584T3/pl unknown
- 2007-02-21 PL PL15184078T patent/PL3020729T3/pl unknown
- 2007-02-21 MY MYPI20083190A patent/MY146664A/en unknown
- 2007-02-21 HU HUE15184078 patent/HUE044595T2/hu unknown
- 2007-02-21 WO PCT/US2007/004430 patent/WO2007098170A1/en active Application Filing
- 2007-02-21 KR KR1020147021161A patent/KR101616712B1/ko active IP Right Grant
- 2007-02-21 DK DK07751204.4T patent/DK1991584T3/da active
- 2007-02-21 EP EP07751204A patent/EP1991584B1/en active Active
- 2007-02-21 EP EP15184078.2A patent/EP3020729B1/en active Active
- 2007-02-21 AU AU2007217751A patent/AU2007217751B2/en active Active
- 2007-02-21 PE PE2007000189A patent/PE20080111A1/es active IP Right Grant
- 2007-02-21 MX MX2013009826A patent/MX337778B/es unknown
- 2007-02-21 NZ NZ570878A patent/NZ570878A/en unknown
- 2007-02-21 PT PT15184078T patent/PT3020729T/pt unknown
- 2007-02-21 SG SG2011037538A patent/SG172628A1/en unknown
- 2007-02-21 EP EP11188458.1A patent/EP2431392B1/en not_active Withdrawn - After Issue
- 2007-02-21 RU RU2008134137/10A patent/RU2467016C2/ru active
- 2007-02-21 ES ES15184078T patent/ES2738731T3/es active Active
- 2007-02-22 AR ARP070100742A patent/AR059604A1/es active IP Right Grant
-
2008
- 2008-08-20 HN HN2008001292A patent/HN2008001292A/es unknown
- 2008-08-21 IL IL193605A patent/IL193605A/en active IP Right Grant
- 2008-08-22 ZA ZA200807278A patent/ZA200807278B/xx unknown
- 2008-08-22 CR CR10237A patent/CR10237A/es unknown
- 2008-08-28 NO NO20083715A patent/NO20083715L/no not_active Application Discontinuation
- 2008-09-19 EC EC2008008751A patent/ECSP088751A/es unknown
-
2009
- 2009-01-06 HK HK09100101.7A patent/HK1120813A1/xx unknown
- 2009-05-29 US US12/474,644 patent/US8187603B2/en active Active
-
2010
- 2010-01-29 US US12/696,434 patent/US8182817B2/en active Active
-
2012
- 2012-05-22 US US13/477,717 patent/US8470993B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY146664A (en) | Antibodies against human il-22 and uses therefor | |
| TW200744634A (en) | Methods of using antibodies against human IL-22 | |
| EP1603949B8 (en) | Antibodies against human il-21 receptor and uses therefor | |
| NZ599875A (en) | Human il-23 antigen binding proteins | |
| IL169152A0 (en) | Antibodies against pd-1 and uses therefor | |
| TW200745163A (en) | Peptides that block the binding of IgG to FcRn | |
| PH12014502527B1 (en) | St2 antigen binding proteins | |
| MY160590A (en) | Cd127 binding proteins | |
| MY181422A (en) | Human antibodies to fel d1 and methods of use thereof | |
| MY150400A (en) | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof | |
| MY149448A (en) | Interleukin-21 receptor binding proteins | |
| AR072136A1 (es) | Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21 | |
| TH97938A (th) | แอนติบอดีต่อต้าน il-22 ของมนุษย์และวิธีการใช้สำหรับการนั้น | |
| TH97938B (th) | แอนติบอดีต่อต้าน il-22 ของมนุษย์และวิธีการใช้สำหรับการนั้น | |
| ECSP056015A (es) | Anticuerpos contra el receptor de il-21 humano y usos de los mismos |